Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), ...
Respiratory syncytial virus was linked to elevated incidence of cardiovascular events in older adults. Future research will ...
GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...
(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's ...
The death of actor and leading man Val Kilmer is a stark reminder of how one of the most common lung infections in the ...
Zacks Investment Research on MSN5d
PFE Secures EU Nod for Expanded Use of RSV Vaccine AbrysvoPfizer PFE announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its RSV ...
Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...
COVID, flu and RSV levels have already hit their peaks. (Pollen levels and springtime allergies are a whole different story.) ...
Pharmaceutical Technology on MSN6d
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSKAbrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...
Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...
(NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO ®, the company’s bivalent respiratory syncytial virus (RSV) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback